Effect of Aprotinin and Avifavir
Adolescent
Adult
Aged
Antiviral Agents
/ therapeutic use
Aprotinin
/ therapeutic use
Cohort Studies
Drug Therapy, Combination
Female
Hospitalization
Humans
Hydroxychloroquine
/ therapeutic use
Intensive Care Units
/ statistics & numerical data
Male
Middle Aged
Pneumonia, Viral
/ drug therapy
Prospective Studies
Russia
SARS-CoV-2
/ drug effects
Treatment Outcome
Young Adult
COVID-19 Drug Treatment
COVID-19
SARS-CoV-2
aprotinin
favipiravir
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
27 06 2021
27 06 2021
Historique:
received:
12
06
2021
revised:
23
06
2021
accepted:
25
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
16
7
2021
Statut:
epublish
Résumé
COVID-19 is a contagious multisystem inflammatory disease caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We studied the efficacy of Aprotinin (nonspecific serine proteases inhibitor) in combination with Avifavir
Identifiants
pubmed: 34199134
pii: v13071253
doi: 10.3390/v13071253
pmc: PMC8310315
pii:
doi:
Substances chimiques
Antiviral Agents
0
Hydroxychloroquine
4QWG6N8QKH
Aprotinin
9087-70-1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
JAMA. 2020 Dec 1;324(21):2165-2176
pubmed: 33165621
Am J Health Syst Pharm. 2005 Sep 15;62(18 Suppl 4):S9-14
pubmed: 16227196
Stat Med. 2001 Mar 30;20(6):859-66
pubmed: 11252008
Curr Protein Pept Sci. 2003 Jun;4(3):231-51
pubmed: 12769721
Cells. 2020 Oct 30;9(11):
pubmed: 33143316
Br J Pharmacol. 2020 Nov;177(21):4813-4824
pubmed: 32329520
J Thorac Cardiovasc Surg. 1999 Aug;118(2):348-53
pubmed: 10425009
Med Drug Discov. 2020 Sep;7:100052
pubmed: 32537610
Ann Thorac Surg. 2001 Feb;71(2):745-54
pubmed: 11235755
Clin Infect Dis. 2020 Aug 09;:
pubmed: 32770240
Radiology. 2005 Sep;236(3):1067-75
pubmed: 16055695
N Engl J Med. 2020 Nov 19;383(21):2041-2052
pubmed: 32706953
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651